Milvexian

Boerner
Favicon Fierce Pharma

Bristol Myers CEO pledges to 'cast a broad net' in dealmaking

BMS completed $30 billion worth of deals in the past two years. Still, “business development remains a top priority,” CEO Chris Boerner said.
Angus Liu Jan 12, 2026 4:28pm
JNJ

J&J trims the edges of its pipeline, mum on timing of new data

Jan 24, 2023 10:54am
neural regeneration

BMS, J&J's secondary stroke med doesn't stick the landing

Aug 28, 2022 3:36am